Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O15013
UPID:
ARHGA_HUMAN
Alternative names:
-
Alternative UPACC:
O15013; O14665; Q2KHR8; Q68D55; Q8IWD9; Q8IY77
Background:
Rho guanine nucleotide exchange factor 10 (RhoGEF10) is a pivotal protein implicated in the regulation of the Rho family GTPases, key modulators of the cytoskeleton organization. This protein's involvement in developmental myelination of peripheral nerves highlights its critical role in nerve function and structure.
Therapeutic significance:
The association of RhoGEF10 with slowed nerve conduction velocity, a condition characterized by reduced nerve conduction speeds without overt neurological dysfunction, underscores its therapeutic potential. Understanding the role of Rho guanine nucleotide exchange factor 10 could open doors to potential therapeutic strategies for improving nerve conduction and treating related neuropathies.